| Title |
Cost-Effectiveness of Dabigatran versus Genotype-Guided Management of Warfarin Therapy for Stroke Prevention in Patients with Atrial Fibrillation
|
|---|---|
| Published in |
PLOS ONE, June 2012
|
| DOI | 10.1371/journal.pone.0039640 |
| Pubmed ID | |
| Authors |
Joyce H. S. You, Kia K. N. Tsui, Raymond S. M. Wong, Gergory Cheng |
| Abstract |
Dabigatran is associated with lower rate of stroke comparing to warfarin when anticoagulation control is sub-optimal. Genotype-guided warfarin dosing and management may improve patient-time in target range (TTR) and therefore affect the cost-effectiveness of dabigatran compared with warfain. We examined the cost-effectiveness of dabigatran versus warfarin therapy with genotype-guided management in patients with atrial fibrillation (AF). |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Germany | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 108 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 4 | 4% |
| Slovenia | 1 | <1% |
| Unknown | 103 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 24 | 22% |
| Researcher | 19 | 18% |
| Student > Bachelor | 12 | 11% |
| Student > Ph. D. Student | 9 | 8% |
| Student > Postgraduate | 8 | 7% |
| Other | 18 | 17% |
| Unknown | 18 | 17% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 50 | 46% |
| Pharmacology, Toxicology and Pharmaceutical Science | 8 | 7% |
| Economics, Econometrics and Finance | 8 | 7% |
| Social Sciences | 5 | 5% |
| Agricultural and Biological Sciences | 5 | 5% |
| Other | 11 | 10% |
| Unknown | 21 | 19% |